Molecular dynamic simulations revealed that ensartinib exhibited favorable binding to c-MET. Ensartinib was highly effective in inhibiting the kinase activity of the MET exon 14 deletion protein (IC50 = 7.9 nM). Furthermore, ensartinib potently suppressed the MET pathway and the growth of Hs746T cells that were subcutaneously implanted into mice. Most importantly, of 17 patients with 14 different types of MET exon 14 skipping mutations undergoing ensartinib treatment, 1 (6%) showed a complete response, 11 (65%) achieved a partial response, and 4 (24%) exhibited stable disease. Thus, the objective response rate (ORR) was 71% and the disease control rate (DCR) was 94%, and the ORR in MET-TKI naive patients was even higher (12/15, 80%). In 2 patients with brain metastasis without prior brain radiation, we observed one partial response in the brain, while in the other patient the brain lesions were stable for 6 months. The most frequently reported adverse events were rash, peripheral edema, and nausea; however, no fatal adverse events occurred.
再次看到恩沙替尼 |
怀疑腺转小 活检出来还是腺
主治医生特意交代尽量穿刺原发灶增大部分的组织了，活检免疫组化出来还是腺。免疫表达
肺腺癌区域转移加脑转骨转ALK突变单
各位前辈，本人去年2022年9月确诊肺腺癌，伴区域转移、脑转、骨转、肌转，ALK突变，单
发现招募：儿童神经母细胞瘤患者（天
招募：儿童神经母细胞瘤患者
地点：天津市肿瘤医院
该院儿童肿瘤科目前正在开展由
发现招募：IgA肾病（IgAN）患者（四
招募：IgA肾病（IgAN）患者
地点：四川大学华西医院（肾脏内科）
研究药物：Ravuli
发现招募：复发/转移性头颈鳞癌患者
招募：复发/转移性头颈鳞癌患者
地点：四川大学华西医院头颈肿瘤科
研究主题：
AK112
显身卡
